Added by Stats. 2017, Ch. 611, Sec. 1. (AB 265) Effective January 1, 2018.
The prohibitions in Sections 132000 and 132002 shall not apply to any of the following:
(a)A discount, repayment, product voucher, or other payment to a patient or another person on the patient’s behalf for a prescription drug required under a United States Food and Drug Administration Risk Evaluation and Mitigation Strategy for the purpose of monitoring or facilitating the use of that prescription drug in a manner consistent with the approved labeling of the prescription drug.
(b)A single-tablet drug regimen for treatment or prevention of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome
(AIDS) that is as effective as a multitablet regimen, unless, consistent with clinical guidelines and peer-reviewed scientific and medical literature, the multitablet regimen is clinically equally effective or more effective and is more likely to result in adherence to the drug regimen.
(c)The individual has completed any applicable step therapy or prior authorization requirements for the branded prescription drug as mandated by the individual’s health insurer, health care service plan, or other health coverage.
(d)A discount, repayment, product voucher, or other reduction in
an individual’s out-of-pocket expenses is not associated with his or her health insurance, health care service plan, or other health coverage.
(e)Rebates received by a state agency.
Cite this section